Design, synthesis, biological evaluation and molecular modelling studies of novel quinoline derivatives against Mycobacterium tuberculosis. Bioorg Med Chem. 2009;17:2830–41.PubMedCrossRef 51. Lounis N, Gevers T, Van den Berg J, Vranckx L, Andries K. ATP synthase inhibition of Mycobacterium avium is not bactericidal. Antimicrob Agents Chemother. 2009;53:4927–9.PubMedCentralPubMedCrossRef 52. Gelber R, Andries K, Paredes RM, Andaya CE, Burgos J. The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and C188-9 administered intermittently. Antimicrob Agents Chemother. 2009;53:3989–91.PubMedCentralPubMedCrossRef 53. Ji B, Chauffour A, Andries
K, Jarlier V. Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice. Antimicrob Agents Chemother. 2006;50:1558–60.PubMedCentralPubMedCrossRef selleck screening library 54. Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother. 2007;51:4202–4.PubMedCentralPubMedCrossRef HMG-CoA Reductase inhibitor 55. Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52:2831–5.PubMedCentralPubMedCrossRef 56. Diacon AH, Dawson R, Von Groote-Bidlingmaier F, et al. Randomized dose-ranging study of the 14-day early bactericidal
activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother. 2013;57:2199–203.PubMedCentralPubMedCrossRef 57. Dooley KE, Park JG, Swindells S, ACTG 5267 Study Team, et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Immune Defic Syndr. 2012;59:455–62.PubMedCentralPubMedCrossRef 58. Svensson EM, Aweeka F, Park JG, Marzan NADPH-cytochrome-c2 reductase F, Dooley KE, Karlsson MO. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested
dose adjustments for patients co-infected with HIV and tuberculosis. Antimicrob Agents Chemother. 2013;57:2780–7.PubMedCentralPubMedCrossRef 59. Wallis RS, Jakubiec W, Mitton-Fry M, et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS One. 2012;7:e30479.PubMedCentralPubMedCrossRef 60. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-Day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet. 2012;380:986–93.PubMedCrossRef 61. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9:640–5.PubMed 62. Sidak Z. Confidence regions for the means of multivariate normal distributions.